KolmarBNH

콜마비앤에이치 · 200130

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$219.1M (₩302.4B)

Overview

KolmarBNH develops and produces health supplements and cosmetics, everyday wellness products such as immune-support and digestive-health foods, as well as skincare, on an ODM/OEM basis, meaning it manufactures finished goods to other brands' specifications.

It supplies customers across South Korea and exports to more than two dozen countries, including China, the United States, and Japan. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the majority of its revenue from health supplements, with cosmetics making up most of the remainder.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$416.6M
▼ −6.6% YoY
Operating profit · FY2025
US$19.3M
▲ +8.2% YoY
Net income · FY2025
−US$16.4M
Turned to loss

Revenue

  • FY2023US$420M
  • FY2024US$446.1M
  • FY2025US$416.6M

Operating profit

  • FY2023US$21.9M
  • FY2024US$17.8M
  • FY2025US$19.3M

Net income

  • FY2023US$13.6M
  • FY2024US$12.5M
  • FY2025−US$16.4M

Key ratios (FY2025)

ROE
-6.4%
Debt/Eq
82.8%
Op. margin
4.6%
Net margin
-3.9%
Rev. YoY
▼ −6.6%

Why it matters

A subsidiary, 근오농림㈜, grows and supplies raw botanical ingredients, including Korean medicinal herbs, directly to the group, giving it an in-house upstream materials capability.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.